Objectif
The Parkinson-Plus syndromes, Multiple System Atrophy and Progressive Supranuclear Palsy (MSA & PSP) are rapidly progressive neurodegenerative diseases, leading to severe disability and death. They are orphan diseases with neither symptomatic nor curative therapy. We will
(i) establish whether the antiexcitotoxic drugriluzole can slow the disease progression,
(ii) provide for the first time prospective data on their natural history. In U. K., France, and Germany, 800patients, stratified on MSA or PSP, will randomly be assigned to placebo orriluzole and followed double blind for 36 months. The primary efficacy criterionis survival.
The project will validate diagnostic staging, new assessment instruments and disease severity staging;
assess cognitive function, quality of life and health economics;
and establish DNA and tissue banks for basic research.
The project will comply with the GMP, GCP, GLP and GSP specifications.
Champ scientifique
Appel à propositions
Data not availableRégime de financement
CSC - Cost-sharing contractsCoordinateur
SE5 8AF LONDON
Royaume-Uni